Cancer represents a heightened risk for home loan insurance, often leading to extra premiums or outright denials for borrowers with a current or past diagnosis. Yet, viable options exist to help these individuals pursue their homeownership dreams. As experts in French mortgage insurance, we've guided countless clients through this process—here's what you need to know.
Cancer can affect any organ or tissue, with prevalent types in France including breast cancer (in both men and women), skin, colon, and digestive cancers. Not all cancers pose the same risk in borrower insurance assessments. Some, like those without curative treatments or prone to sudden progression, are particularly challenging. Medical experts' evaluations are pivotal: insurers may refuse coverage or apply surcharges based on severity.
Our experience shows that early detection and treatment advances improve outcomes, but insurers scrutinize each case individually for accurate risk assessment.
Advancements in treatments have made cancer remission achievable, depending on the type and early detection. However, insurers often view survivors as higher-risk, previously requiring disclosure and surcharges.
The 2016 health law introduced the 'right to be forgotten,' enabling eligible survivors to omit their history and access standard-rate insurance. This applies to specific cancers with defined remission periods: 1 year for cervical and breast cancers; 3-10 years for prostate cancer. We've helped many clients leverage this to secure favorable terms without disclosure.
To maximize approval odds with or post-cancer, use a trusted online borrower insurance comparator for tailored quotes. If refused, request detailed reasons to prepare a rebuttal—though success isn't guaranteed.
The AERAS convention offers a proven path, standardizing coverage without surcharges or exclusions. Alternatives include personal guarantees, real estate mortgages, or third-party sureties. Co-borrowing is another strategy: only the affected borrower faces restrictions, with balanced quotas easing funding. In our advisory practice, these solutions have unlocked financing for numerous clients.
